miRagen Therapeutics, Inc, a biopharmaceutical company working to develop microRNA-based therapeutic agents for a range of diseases, recently announced the initiation of a Phase I clinical study assessing MRG-201, the company’s lead anti-fibrotic candidate, in healthy patients. The study has the potential to be extended to patients with cutaneous scleroderma.
MRG-201 has been previously shown to reverse fibrosis in a mouse model of pulmonary fibrosis. It is a synthetic microRNA mimic (promiR) to microRNA-29b, part of a family of microRNAs (miRNAs) known to be powerful negative regulators of gene expression related to extracellular matrix deposition. The three main mature miRNAs in this family are under-expressed in several diseases with a pathological fibrotic component, such as systemic sclerosis (scleroderma), and cardiac, renal and pulmonary fibrosis. A number of cell culture in vitro and animal in vivo studies have demonstrated the potential of miRNA-29 molecules in the reduction and treatment of disease-causing fibrosis.
The Phase 1 trial will test the safety, tolerability, and dose-range of of MRG-201 in comparison with a placebo, and is the first step in its potential development as a treatment for fibrotic cutaneous diseases and other fibrotic pathologies, including scleroderma.
William Marshall, Chief Executive Officer of miRagen Therapeutics, said of the announcement in a press release, “As a company dedicated to improving human health through the discovery and development of innovative RNA-targeting therapies like MRG-201, we are excited by this event. The initiation of this clinical trial advances a potentially important new therapy for patients suffering from pathological fibrosis and is an example of our focus on areas of high unmet medical need.”
The potential role of miRNA-29 in pathological fibrosis was first identified by researchers at miRagen in a partnership with Dr. Eric N. Olson’s research team at the University of Texas Southwestern Medical Center. miRagen Therapeutics, which has in-house expertise in miRNA biology and oligonucleotide chemistry, is in the second year of a grant to explore developing MRG-201 as a possible treatment of progressive lung fibrosis. That work is being done in collaboration with Yale University and with a Centers for Advanced Diagnostics and Experimental Therapeutics grant from the National Institutes of Health (NIH).
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?